Building Capability for Clinical Pharmacology Research in Sub-Saharan Africa.

P Sinxadi, B Ogutu, J Spector, T Gebre-Mariam, G Yimer, M Munyoro, C Masimirembwa, S Abdulla, E Allen, M M Gutierrez, K I Barnes, K P Asante, S Owusu-Agyei, K O Onyango, F Romero, S Felix, G Pillai

Journal: Clinical pharmacology and therapeutics 2017;102(5):786-795

PMID: 28378903

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

A strong scientific rationale exists for conducting clinical pharmacology studies in target populations because local factors such as genetics, environment, comorbidities, and diet can affect variability in drug responses. However, clinical pharmacology studies are not widely conducted in sub-Saharan Africa, in part due to limitations in technical expertise and infrastructure. Since 2012, a novel public-private partnership model involving research institutions and a pharmaceutical company has been applied to developing increased capability for clinical pharmacology research in multiple African countries.

Address: Novartis Pharma and Novartis Institutes for Biomedical Research, Basel, Switzerland and Cambridge, Massachusetts, USA.; Kenya Medical Research Institute (KEMRI)/Strathmore University (SU), Nairobi, Kenya.; Kintampo Health Research Center, Kintampo, Ghana.; University of Cape Town, Cape Town, South Africa.; Ifakara Health Institute, Bagamoyo, Tanzania.; African Institute of Biomedical Science & Technology, Harare, Zimbabwe.; Addis Ababa University/Regional Bioequivalence Center, Addis Ababa, Ethiopia.

DOI: 10.1002/cpt.695

Link outs

Free resources

Other Literature Sources:

https://scite.ai/reports/28378903

Subscription / membership required

Full Text Sources:

MeSH Terms: Africa South of the Sahara, Biomedical Research, Clinical Trials as Topic, Humans, International Cooperation, Pharmacogenetics, Pharmacology, Clinical, Public-Private Sector Partnerships